These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25378228)

  • 1. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.
    Okamura I; Imai H; Mori K; Ogura K; Isoda A; Mihara K; Matsumoto M; Saito R; Takahashi T; Ikeda T
    Int J Hematol; 2015 Jan; 101(1):46-51. PubMed ID: 25378228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
    Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
    Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
    J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study.
    Amiot A; Lévy M; Copie-Bergman C; Dupuis J; Szablewski V; Le Baleur Y; Baia M; Belhadj K; Sobhani I; Leroy K; Haioun C; Delchier JC
    Aliment Pharmacol Ther; 2014 Mar; 39(6):619-28. PubMed ID: 24467480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
    Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
    Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.
    Seker M; Bilici A; Ustaalioglu BO; Salman T; Sonmez B; Canpolat NA; Salepci T; Gumus M; Yaylaci M
    Leuk Res; 2009 Sep; 33(9):e154-6. PubMed ID: 19386361
    [No Abstract]   [Full Text] [Related]  

  • 9. Regression of pulmonary MALT lymphoma after treatment with rituximab.
    Chong EA; Svoboda J; Cherian S; Andreadis C; Downs LH; Zhuang H; Alavi A; Tsai DE; Schuster SJ
    Leuk Lymphoma; 2005 Sep; 46(9):1383-6. PubMed ID: 16109620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful rituximab monotherapy in a patient with mucosa-associated lymphoid tissue lymphoma of the rectum with trisomy 3, 18].
    Kagawa M; Okamura S; Okamoto K; Kitamura S; Kimura T; Niki M; Kaji M; Okahisa T; Yano M; Kagawa S; Kudo E; Sano T; Imoto Y; Wada S; Takayama T
    Nihon Shokakibyo Gakkai Zasshi; 2010 Apr; 107(4):612-9. PubMed ID: 20379095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytic differentiation in MALT lymphomas following treatment with rituximab.
    Troch M; Kiesewetter B; Dolak W; Jaeger U; Püspök A; Müllauer L; Chott A; Raderer M
    Ann Hematol; 2012 May; 91(5):723-728. PubMed ID: 22186828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME; Raderer M
    Hematol Oncol; 2017 Jun; 35(2):177-186. PubMed ID: 26580149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
    Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
    Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population.
    Ogusa E; Tomita N; Ishii Y; Takasaki H; Hattori Y; Matsumoto C; Ishigatsubo Y
    Hematol Oncol; 2013 Mar; 31(1):18-21. PubMed ID: 22278757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifocal extranodal mucosa-associated lymphoid tissue lymphoma affecting the larynx.
    Arndt S; Veelken H; Schmitt-Gräff A; Aschendorff A; Maier W; Richter B
    Ann Otol Rhinol Laryngol; 2007 Apr; 116(4):257-61. PubMed ID: 17491523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
    Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
    Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
    Kiesewetter B; Lamm W; Neuper O; Mayerhoefer ME; Simonitsch-Klupp I; Raderer M
    Hematol Oncol; 2019 Oct; 37(4):345-351. PubMed ID: 31283840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
    Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
    Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of localized oral MALT lymphoma by rituximab: a case report.
    Yamagata K; Onizawa K; Kojima H; Yoshida H
    Oral Maxillofac Surg; 2008 Dec; 12(4):227-30. PubMed ID: 18830723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.